Form 4: Beam Therapeutics CMO Amy Simon Granted 12,500 RSUs

Beam Therapeutics' Chief Medical Officer, Amy Simon, was granted 12,500 restricted stock units, vesting over four years.

Summary

• Amy Simon, Chief Medical Officer of Beam Therapeutics Inc. (BEAM), acquired 12,500 shares of common stock.
• The acquisition was in the form of Restricted Stock Units (RSUs) granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan.
• Each RSU represents the contingent right to receive one share of BEAM's common stock.
• The RSUs vest in four substantially equal installments on each of the first four anniversaries of the grant date, subject to continued service.
• Following this transaction, Amy Simon beneficially owns 77,364 shares of common stock directly.
• The transaction date for the RSU grant was December 31, 2025, with a price of $0.00 per RSU.

Sentiment

Score: 7

Explanation: The RSU grant is a positive signal for executive retention and alignment of interests, but it is a routine compensation event and not indicative of new operational performance or strategic shifts.

Positives

• The grant of Restricted Stock Units (RSUs) to the Chief Medical Officer aligns her long-term interests with those of shareholders, promoting retention and incentivizing performance.
• The use of an existing 2019 Equity Incentive Plan demonstrates a structured approach to executive compensation.

Future Outlook

The vesting schedule of the RSUs over four years indicates an expectation of continued service from the Chief Medical Officer, aligning her incentives with the company's long-term success.

Industry Context

The grant of Restricted Stock Units (RSUs) is a standard and widely adopted practice in the biotechnology and pharmaceutical industries for executive compensation. It serves as a key mechanism to attract, retain, and motivate senior leadership by linking their personal wealth directly to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• The RSU grant structure, with a multi-year vesting schedule contingent on continued service, is a common compensation practice for executives in biotech companies like Moderna, BioNTech, and CRISPR Therapeutics, aiming to ensure long-term commitment and alignment with shareholder interests.
• The grant price of $0.00 for RSUs is standard, as RSUs represent a right to receive shares upon vesting, rather than an option to purchase at a set price.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Medical Officer's financial interests with long-term shareholder value creation, potentially leading to more focused strategic decisions.
• Employees: This type of executive compensation can set a precedent for performance-based incentives within the company, potentially influencing broader compensation strategies.

Next Steps

• The RSUs will vest in four substantially equal installments on each of the first four anniversaries of the grant date (December 31, 2025), subject to Amy Simon's continued service with Beam Therapeutics Inc.

Key Dates

Recommendation

This is a routine insider transaction (RSU grant) for executive compensation and retention, which does not fundamentally alter the investment thesis for Beam Therapeutics. It aligns management's interests with shareholders but doesn't provide new operational or financial data to warrant a change in recommendation.

Keywords

Beam Therapeutics, BEAM, Restricted Stock Units, RSU, Insider Transaction, Form 4, Equity Incentive Plan, Amy Simon, Chief Medical Officer